A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Clinical trial NCT03909971 · COMPLETED

Trial details

NCT number: NCT03909971
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2019-04-28
Primary completion: 2020-08-10
Enrollment: 109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.